Cancer Advances, Inc. Announces Issuance of New U.S. Patent
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S. Patent and Trademark Office has issued new patent No. 11,583,576, enhancing the Company’s intellectual property position for lead asset Polyclonal Antibody Stimulator (PAS) vaccine. The new patent titled “Compositions and Methods for Inducing Humoral and Cellular Immunities against Tumors and Cancer” covers a method for treating and/or preventing and/or inhibiting development of a tumor and/or a cancer associated with gastrin signaling in a subject. Gastrin mediated tumors include, but are not limited to, gastrointestinal cancers.
The novel IP further covers methods for treatment of GI cancer by administering PAS followed by an immune checkpoint inhibitor. A related claim covers reduction in fibrosis associated with pancreatic cancer via the administration of this combination.
“After more than six years of research, we are excited to have this patent issued. We have known that PAS can induce the development of antibodies to Gastrin, bringing Gastrin levels down and increasing survival times by 50% in GI clinical trials. With our research now demonstrating that PAS is able to alter the tumor microenvironment, it opens the door to many new opportunities to improve current treatment for GI cancer patients,” commented Lynda Sutton, President of Cancer Advances.
The issued patent adds to the over one hundred granted global patents for PAS. Cancer Advances plans to seek approval for PAS in the treatment of gastric and pancreatic cancers.
About Cancer Advances, Inc.
Cancer Advances Inc. (Durham, NC) is a biotechnology company focused on impacting human health and preventing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team with over one hundred and twenty years of combined experience in drug development and commercialization experience.
About Polyclonal Antibody Stimulator (PAS)
Polyclonal Antibody Stimulator (PAS) vaccine is an immunomodulator potentially applicable in multiple cancer types including gastric, pancreatic, and colorectal. The vaccine is a peptide-conjugate that includes an N-terminal epitope of human gastrin-17 (G17) linked to carrier diphtheria toxoid. PAS has been studied in multiple clinical trials, in over 1,500 human subjects, and has demonstrated an excellent safety and tolerability profile. Cancer Advances exclusively owns PAS and is funding and managing all aspects of the PAS gastrin vaccine program.
Contact
Cancer Advances, Inc.
E-mail: jwingen@canceradvances.com
https://www.canceradvances.com/
https://www.linkedin.com/company/cancer-advances/
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
New member proposed for election to the Board of Directors21.3.2023 14:38:36 CET | Press release
Company announcement no 6-2023 Copenhagen, March 21, 2023 New member proposed for election to the Board of Directors Konsolidator’s Board of Directors proposes that Peter Gath is elected as a new member of the Board of Directors at the company’s upcoming Annual General Meeting scheduled for 23 March 2023. Consequently, Konsolidator’s Board of Directors proposes that the company’s Board of Directors will consist of five members: the Chairman of the Board, Jesper Eigen Møller, and the members Thomas Aporta, Cecilia Hultén, Claus Jul Christiansen, and Peter Gath. Peter Gath enters the Board of Directors with over 20 years of experience as a partner from EY and KPMG. Peter is currently CFO of St. Jørgen Holding and holds multiple Board Member positions, incl. in the listed company Brødrene A & O Johansen A/S. As a Chartered Accountant with a background in audit and leadership, as well as an Adjunct Professor at Copenhagen Business School (CBS) and former Chairman of the Danish Institute of
SELIGSON & CO OMX HELSINKI 25 EXCHANGE TRADED FUND UCITS ETF: ANNUAL REPORT, BOARD OF THE MANAGEMENT COMPANY AND AUDITOR21.3.2023 14:30:00 CET | Press release
Seligson & Co Fund Management Company Plc STOCK EXCHANGE NOTICE 21 March 2023 SELIGSON & CO OMX HELSINKI 25 EXCHANGE TRADED FUND UCITS ETF: ANNUAL REPORT, BOARD OF THE MANAGEMENT COMPANY AND AUDITOR The Annual Report of Seligson & Co OMX Helsinki 25 Exchange Traded Fund UCITS ETF, dated 31 December 2022, has been published. The report, which is in Finnish, forms part (pages 41 to 47) of the attached common Annual Report for the Seligson & Co funds. The report and the Auditor's Report are also available at www.seligson.fi/sco/suomi/esitteet/. The following members were elected to the board of Seligson & Co Fund Management Company Plc at the Annual General Meeting held on 21 March 2023: Samu Anttila, Jarkko Niemi and Mikko Vasko. KPMG Plc was chosen as the auditor and CPA Marcus Tötterman as the deputy auditor. Further information: Mari Rautanen email: mari.rautanen@seligson.fi Phone +358 (0)9 6817 8224 Seligson & Co Fund Management Company Plc Ari Kaaro Managing Director email: ari.kaar
Ledende medarbejdere og disses nærtstående transaktioner.21.3.2023 14:09:36 CET | pressemeddelelse
Nasdaq Copenhagen Silkeborg, den 21. marts 2023 Fondsbørsmeddelelse nr. 2 / 2023 Vedr.: Ledende medarbejdere og disses nærtstående transaktioner. I henhold til Markedsmisbrugsforordningen art. 19 oplyser Silkeborg IF Invest A/S at have modtaget følgende meddelelse om erhvervelse af selskabets aktier: Navn: Silkeborg Fodbold Holding A/S Årsag: Silkeborg Fodbold Holding A/S ejes af Kent Villadsen Madsen, der er adm. direktør i Silkeborg IF Invest A/S. Udsteder: Silkeborg IF Invest A/S Fondskode: DK0010128008 Betegnelse: Aktie Transaktion: Køb Handelsdato: 20.03.2023 Marked: NASDAQ OMX Copenhagen A/S Antal: 10.000 stk. Kursværdi: 186.955,80 DKK. Eventuelle henvendelser vedr. nærværende fondsbørsmeddelelse bedes venligst rettet til undertegnede. Med venlig hilsen Silkeborg IF Invest A/S Kent Madsen Claus Christensen Adm. direktør Økonomidirektør Vedhæftet fil 2. Ledende medarbejdere og disses nærtstående transaktioner (20230321)
Fortinet Annual Skills Gap Report Uncovers an Increase in Breaches Attributed to a Lack of Cybersecurity Skills21.3.2023 14:00:00 CET | Press release
New Fortinet research reveals escalating cyber risks due to the ongoing talent shortage while the number of organizations experiencing five or more breaches jumped by 53% SUNNYVALE, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- John Maddison, EVP of Products and CMO at Fortinet “The cybersecurity talent shortage is one of the top challenges putting organizations at risk, as clearly demonstrated by the results of the latest Global Cybersecurity Skills Gap Report from Fortinet. In today’s climate, organizations must choose products that introduce automation to offload overworked teams while continuing to focus on upskilling and cybersecurity training.” News Summary Fortinet® (NASDAQ: FTNT), the global cybersecurity leader driving the convergence of networking and security, today released its 2023 Global Cybersecurity Skills Gap Report, which reveals ongoing challenges related to the cybersecurity skills shortage affecting organizations worldwide. Key findings from the global report include:
INDKALDELSE TIL ORDINÆR GENERALFORSAMLING 202321.3.2023 13:41:17 CET | Press release
__________________________________________________________ INDKALDELSE TIL ORDINÆR GENERALFORSAMLING 2023 ERRIA A/S CVR-NR. 15300574 __________________________________________________________ Tidspunkt: onsdag, 12. april 2023 kl. 11:00 Sted: Duevang, Sankt Gertrudsstræde 2, 4600 Køge Bestyrelsen foreslår advokat Martin Skovbjerg, Bag Haverne 32, 4600 Køge, som dirigent. Dagsordenen er følgende: 1.Bestyrelsens beretning for selskabets virksomhed i det forløbne år.2.Forelæggelse af revideret årsrapport til godkendelse.3.Beslutning om anvendelse af overskud eller dækning af underskud i henhold til den godkendte årsrapport.Bestyrelsen indstiller, at årets resultat overføres til næste år. 4.Beslutning om decharge til bestyrelse og direktionen.Bestyrelsen indstiller, at der meddeles decharge til bestyrelsen og direktionen. 5.Valg af medlemmer til bestyrelsen.Følgende personer indstilles genvalgt til bestyrelsen: Søren Storgaard, Køge Kristian Svarrer, Esbjerg Ng Sing King, Singapore 6.Valg a